Poziotinib

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NamePoziotinib
Drug Alias NamePoziotinibum珀齐替尼HM-781-36B hydrochloride泊齐替尼Poziotinib hydrochloride +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaDiscontinued
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSpectrum PharmaceuticalsLuye Pharma Group LtdThe University Of Texas MD Anderson Cancer Center +[4] 
Inactive CompaniesHanmi Pharmaceutical Co LtdYonsei UniversityKonkuk University Medical Center
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsMetastatic breast cancerSolid tumoursLung Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A